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Summary 
Molecules representative of different classes of chemotactic agents, including formyl-Met-Leu- 
Phe (FMLP),  CSa, leukotriene B4, platelet-activating  factor, and interleukin (IL)-8, caused a 
rapid reduction in the IL-1 binding capacity by human polymorphonuclear leukocytes (PMN), 
a cell type expressing predominantly the IL-1 type II decoy receptor (IL-1 decoy RII). N-t-Boc- 
Met-Leu-Phe, an antagonist  for the FMLP receptor, inhibited the loss of IL-1 binding capacity 
induced by FMLP. Monocyte chemotactic protein 1, a chemokine related to IL-8 but inactive 
on PMN, had no effect on IL-1 binding in this cell type. FMLP was selected for further detailed 
analysis of chemoattractant-induced loss of IL-1 binding by PMN. The action of FMLP was 
rapid,  reaching 50% of its maximum (80%) at 30 s,  the earliest measurable time point, and 
plateauing between 10 and 30 min. Dose-response  analysis revealed that maximal reduction of 
IL-1 binding was reached at FMLP concentrations  that were also optimal for chemotaxis (50% 
effective dose  =  5  x  10 -9  M).  The loss of IL-1 binding capacity caused by FMLP was 
determined by a reduction in receptor number with no change in their affinity. The effect of 
FMLP on IL-1 receptor (IL-1R) was selective in that the PMN surface structures IL-SR, CD16, 
CD18, and major histocompatibility complex class I antigens were unaffected  under these conditions. 
Loss of surface IL-1R was not due to an augumented rate of internalization.  FMLP caused rapid 
release of a 45-kD IL-1-binding molecule identified as the IL-1 decoy RII. After FMLP-induced 
release, PMN reexpressed newly synthesized receptors, reaching basal levels  by 4 h. FMLP-induced 
release of the IL-1 decoy RII did not impair the responsiveness of PMN to IL-1 in terms of 
promotion of survival and cytokine production. FMLP-induced  release of the IL-1 decoy RII 
was unaffected by protein synthesis inhibitors,  was blocked by certain protease inhibitors,  and 
was mimicked by agents  (the Ca + + ionophore A23187 and phorbol myristate acetate) that 
recapitulate elements in the signal transduction pathway of chemoattractant receptors. The time 
frame and concentration range of chemoattractant-induced rapid release of the IL-1 decoy RII 
are consistent with the view that IL-1 decoy RII release is an early event in the multistep process 
of leukocyte recruitment. Rapid chemoattractant-induced IL-1 decoy RII release in the circulation 
may counteract IL-1 leaking into the systemic  circulation from sites of  inflammation while preserving 
the capacity of leukocytes to respond to IL-1 in tissues. This phenomenon may contribute as 
well to the antiinflammatory effect of systemic administration  of chemotactic agents. 
I 
L-lol and IL-13 are potent mediators of immune and inflam- 
matory reactions whose spectrum of activity encompasses 
a number of different cell types (1). Two receptors for IL-1 
termed type I and type II (IL-1RI and IL-1RII), usually coex- 
pressed in different cell types, have been identified and cloned 
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(1, 2). IL-1 signaling activity appears to be mediated exclu- 
sively via the IL-1RI, whereas the IL-1RII has no signaling 
property and acts in myelomonocytic  cells as a decoy for IL-1, 
inhibiting its activity by preventing  IL-1 from binding to 
the IL-1RI  (3,  4). 
A soluble version of IL-1 decoy RII has been identified 
in the supernatants from B lyrnphoblastoid cells (5-7) and 
PHA-activated  human mononuclear cells (8), in human plasma 
(9), and in inflammatory synovial  fluid (8). Recently, we found 
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corticoid, dexamethasone (11), were potent inducers of IL-1 
decoy RII expression and release in human myelomonocytic 
cells. Up-regulation of IL-1 decoy RII by IL-4, IL-13, and 
dexamethasone was gene and protein synthesis dependent. 
The released soluble IL-1 decoy RII retains its ability to bind 
IL-l~x,  IL-1B,  and the  IL-1R antagonist,  although with 
different relative affinities compared to the membrane-bound 
receptor (11). The ability of certain cytokines and glucocor- 
ticoids to induce expression and release of a decoy target for 
IL-1 may contribute to the antiinfhmmatory activities of these 
agents (4,  11). 
Various agents, including chemotactic signals, cause rapid 
shedding of TNFR (12). These previous observations prompted 
us to examine the regulation of IL-1 decoy RII release from 
human PMN exposed to chemotactic stimuli. We found that 
treatment of PMN with chemoattractants results in massive 
(up to 90%), rapid (evident within 30 s), and protein synthe- 
sis-independent release from the PMN surface of a soluble 
form of IL-1 decoy RII, followed by reexpression  of newly 
synthesized receptor.  This event is mediated by a preformed 
proteolytic enzyme. Rapid release of the IL-1 decoy RII is 
an early event in the multistep process of PMN recruitment, 
which likely plays a role in the regulation of local versus sys- 
temic inflammatory reactions. 
Materials and Methods 
Cells.  Human PMN were separated from the peripheral blood 
of human healthy donors by Percoll gradient centrifugation (13). 
Briefly, whole blood was fractionated by Ficoll gradient centrifu- 
gation (Seromed-Biochem  KG, Berlin, Germany), and PMN, col- 
lected from the pellet, were layered  on top of 62% Percoll (Phar- 
macia LKB, Uppsala, Sweden) after a centrifugation at 1,500 rpm 
for 20 min at room temperature. PMN pellets (>~98% pure as as- 
sessed by morphology) were resuspended at 107/ml in RPMI 1640 
(Seromed-Biochem  KG) with 2 mM glutamine (Seromed-Biochem 
KG) and 20 mM Hepes (Merck, Darmstadt,  Germany). All re- 
agents contained  <0.125 EU/ml of endotoxin as checked  by limulus 
amebocyte  lysate  assay  (Microbiological  Associates, Inc., P,  ockvilh, 
MD). 
Reagents.  FMLP was purchased from Sigma Chemical Co. (St. 
Louis, MO), dissolved  in ethanol at 10 -9 M, and stored at  -20~ 
until use. Human recombinant CSa was a kind gift from Dr. H. S. 
Showell (Pfizer Central Research, Groton, CT). Human recom- 
binant ID8 was from Dainippon (Osaka,  Japan). Phtelet-activating 
factor (PAF),  1 leukotriene B4 (LTB4), A23187, PMA, and cyclo- 
heximide (CH) were purchased from Sigma Chemical Co. Human 
recombinant monocyte chemotactic protein (MCP)-I was from 
Pepro Tech Inc. (Rocky Hill, NJ). 
Human recombinant Ibl/~ was obtained through the courtesy 
of Dr. J. E. Sims (Immunex Corp., Seattle, WA). Protease inhibi- 
tors used in this study (PMSF, N-tosyl-lysyl-chloromethyl  ketone 
t Abbreviations used in this paper: CH, cycloheximide;  LTB4, leukotriene 
B4; MCP, monocyte  chemotactic  protein; PAF, platelet-activating  factor; 
PKC, protein  kinase  C; TLCK,  N-tosyl-lysyl-chloromethyl  ketone;  TPCK, 
N-tosyl-phenylalanyl-choromethyl  ketone. 
[TICK], N-tosyl-phenylalanyl-chloromethyl  ketone [TPCK], and 
EGTA) were from Sigma Chemical Co. EDTA was from Merck. 
o~t-antitrypsin was from Calbiochem Corp. (La Jolla, CA). 
ILI-Binding Assay (4, 10, 11).  Routinely, PercoU-purified  PMN 
(107/ml) were incubated with or without the indicated stimuli in 
serum-free medium RPMI 1640 at 37~  in 5~  CO2 for 30 min 
in polypropylene  50-ml conical  tubes (2070; Falcon  Labware,  Becton 
Dickinson and Co., Oxnard, CA). Next, cells were washed with 
binding buffer (RPMI 1640, 0.2~  BSA, pH 7.4 [Sigma Chemical 
Co.]), and 4  x  106 PMN were incubated with 600 pM 12sI-IL-1B 
(sp act 180/~Ci//~g; New England Nuclear, Bad Homburg, Ger- 
many) in the presence or absence of a 100-fold  molar excess of cold 
cytokine in 50/.d binding buffer at 4~  for 18 h in polystyrene 
96 round-bottomed well microplates (3077; Falcon Labware) on 
a shaking platform. Preliminary experiments showed that binding 
reached the plateau (8 h) under these conditions. To separate  bound 
from free ~2sI-IL-1/~,  ceils were resuspended, transferred to Eppen- 
dorf tubes, washed  in binding buffer,  resuspended  in 70 ~l of  binding 
buffer, and finally layered on the top of a 200-/~1 cushion of 20070 
sucrose (Merck) and  107o BSA in  400-#d polypropylene tubes 
(342867; Beckman Instruments, Palo Alto, CA) and centrifuged 
at 10,000 rpm for 30 s at room temperature. The cellular pellets 
were counted in a gamma counter. When IL-8  binding was studied, 
12sI-IL-8 (Amersham International, Little Chalfont, UK) (sp act 
2,000 Ci/mmol) was used under the same experimental condi- 
tions described above. To obtain a saturation curve, untreated or 
FMLP-treated PMN were incubated with decreasing amounts of 
~2sI-IIrl~, in the presence or absence of a 100-fold molar excess 
of cold cytokine. Next, Scatchard analysis was performed by the 
LIGAND (4.1; National Institutes of Health, Bethesda, ME)) pro- 
gram to determine the affinity and numbers of receptors for IblB. 
To investigate the kinetics of loss of II.-1 binding, PMN were in. 
cubated at 107/ml in RPMI 1640 at 37~  for different periods of 
time (30 s-30 rain) in the presence or absence of FMLP. Subse- 
quently, cells were washed and resuspended in binding buffer to 
evaluate Ibl binding as previously described. When reexpression 
of II,1 decoy RII was studied, PMN were pretreated in medium 
or with FMLP for 30 min to induce release of IL-1R from PMN. 
PMN were then washed and incubated in  10%  FCS (Hyclone 
Laboratories, Inc., Logan, UT)  RPMI  1640 medium (recovery 
period) for various periods of time and tested for IL-1B binding. 
ILIR  Internalization.  PMN (4  x  106/50/~1) were incubated 
in binding buffer with I nM 12sI-Ib1B for 4 h at 4~  on a shaking 
platform, in the presence or absence of a 100-fold  molar excess of 
unlabeled IL-1/~. PMN were washed twice in binding buffer to re- 
move  unbound cytokine  and then resuspended  in serum-free  medium 
RPMI 1640 (4  x  106/100/~1) and incubated for various periods 
of time at  37~  with or without  10 -7  M FMLP, to induce 
receptor internalization. At each time point, 4  x  106 cells were 
washed, acid washed  for 5 min (50 mM glycine;  0.8% NaC1, pH 3) 
to remove surface-bound cytokine, and washed again, and pellets 
were counted in a gamma counter to determine the amount of in- 
ternalized cytokine. 
Chemotaxis Assay.  The chemotactic response of human cir- 
culating PMN to FMLP was tested as described (14, 15). Briefly, 
25  _+  1/~1 of FMLP, diluted in 1% FCS RPMI 1640, was seeded 
in the lower compartment of the chemotaxis chamber, and 50 #1 
of cell suspension (1.5  x  106/ml) was seeded in the upper com- 
partment. 
The two compartments were separated by a 5-/~m pore size 
polyvinylpyrrolidone-free  polycarbonate filter (Nuclepore Corp., 
Pleasanton, CA). Chambers were incubated at 37~  in air with 
5% CO2 for 90 min. At the end of the incubation, filters were 
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NJ),  and five high power oil immersion fields were counted. 
Flow Cytometry.  The following antibodies were used for flow 
cytometry: The anti-CD16 mAb KD1 was a kind gift from Dr. 
E. Ciccone (Istituto Tumori, Genova, Italy), and anti-MHC class 
I molecule mAb W6/32 and anti-CD18 mAb T81/18 were from 
American Type Culture Collection (Rockville, MD). After treat- 
ment with FMLP for 30 min as detailed above, an aliquot of cells 
was examined for IL-lfl binding,  and the remaining PMN were 
resuspended in 0.1 ml saline (Bieffe,  Bergamo, Italy) with 2% human 
serum (pool from different healthy donors) and mAb. After 30 min 
of incubation on ice, cells were washed twice and resuspended in 
saline containing 2% human serum and a fluoresceinated antibody 
against mouse IgG (Becton Dickinson Immunocytometry  Systems, 
Mountain View, CA). After 30 min on ice, cells  were washed twice 
and analyzed by flow cytofluorometry  with a FACSTAR  |  plus ap- 
paratus (Becton Dickinson  and Co.). 
Affinity Cross-linking.  Cross-linking experiments were described 
in detail (11). 30  x  106 PMN were stimulated with 10-7 M FMLP 
in I ml of KPMI 1640 at 37~  for 30 min. Medium was recovered 
and concentrated 10 times by membrane filtration (Amicon, Beverly, 
MA; cut-off 10,000). When studied, 200 #1 was added to 1 nM 
128I-Ibl/3, with or without a 200-M excess of cold II~1/3 or 10 
/~g/ml M1 (blocking mAb anti-II.,1KI) or M22 (blocking mAb 
anti-IL-1RII) (16, 17) kindly provided by Dr. J. E. Sims, and in- 
cubated at 4~  for 4 h.  After addition of I  mM disuccinimidyl 
suberate from Pierce Chemical Co. (Rockford, IL) at 4~  for 30 
min, samples were analyzed  by 8% SDS-PAGE  under reducing con- 
ditions, and dried gels were exposed to autoradiography for 1-3 d. 
11_,6  and 11_,8  Production.  PMN were exposed  for 30 min to FMLP 
or medium.  After washing, the cells were pulsed with 20 ng/ml 
of IL-1/3 for 4 h. Finally, cells were washed and incubated for an 
additional 24 h. The supernatants were collected and tested for IL-8 
production by ELISA assays (the antibodies were from Dr. M. Ceska, 
Sandoz Forschung Institut, Vienna, Austria) and for IL-6 produc- 
tion by bioassay, using the 7TD1 hybridoma cell line as previously 
described (18). 
StatisticalAnalysis.  The differences  among experimental groups 
were tested by the Student's  t test. 
Results 
Effects of PMN Chemoattractants on IL-I Binding.  Table 1 
summarizes  the effects of various  agents representative of 
different classes of chemoattractants (formylated peptides, com- 
plement components, lipids, chemokines) on the capacity of 
PMN to bind 125I-IL-1B. The different concentrations of the 
stimuli were chosen according to their optimal activity in 
the chemotactic assay. Results in Table  1 are a compound 
of different experiments and are presented as the percentage 
of binding relative to control at the 30-min time point. FMLP, 
C5a, LTB4, PAF, and IL-8 caused reductions of IL-1 binding 
to PMN of 80% (ranging from 73 to 94%), 50% (from 43 
to 54%), 52% (from 47 to 66%), 37% (from 11 to 30%), 
and 25%  (from 21 to 37%), respectively. The formyl pep- 
tide N-t-Boc-Met-Leu-Phe, an inactive FMLP receptor an- 
tagonist, caused no reduction at high concentrations (10-4 
M) and partially inhibited the activity of FMLP. MCP-1, a 
chemokine that is inactive on PMN  as a chemoattractant, 
caused no loss of IL-1 binding capacity. The signal transduc- 
tion pathways of chemotactic factor serpentine receptors in- 
Table  1.  Loss of IL-1 Binding Capacity in PMN Exposed 
to Different Stimuli 
Treatment  IL-1 binding 
(dose or dilution)  (percentage of control) 
FMLP (10 -7 M)  19.8  +  7.2 (13) 
BOCMLP (10 -4 M)  95.3  +  4.6  (2) 
BOCMLP (10 -4 M)  + 
FMLP (10 -7 M)  55.5  _+  6.3  (2) 
C5a (50 ng/ml)  50.8  +  4.9  (3) 
PAF (10 nM)  63.8  _+  11.6 (2) 
LTB~ (100 nM)  48.8  +  4.9  (2) 
IL-8 (100 ng/ml)  75.0  +  8.2 (3) 
MCP-1  (100 ng/ml)  97.5  +  2.7 (2) 
A23187 (10 -7 M)  8.4  _+  8.1  (3) 
PMA  (10 ng/ml)  41.3  _+  3.6  (2) 
Ethanol  (1:1,000)  98.0 (1) 
DMSO (1:1,000)  99.6 (1) 
Human peripheral  blood  PMN were incubated  with the indicated stimuli 
for 30 min at 37~  and then examined  for surface  binding of 1251-IL-1~. 
Data are expressed as percentage of IL-1 binding over the same PMN 
population cultured in parallel with medium alone. Data are shown as 
mean + SD from the number of independent experiments indicated in 
parentheses. 
clude activation of PKC and a rapid increase in intracellular 
free Ca + +. The protein kinase C (PKC) activator PMA and 
the Ca ++  ionophore A23187 mimicked chemoattractants by 
causing rapid loss of IL-1 binding capacity. Subsequent anal- 
ysis was conducted, mostly with the prototypic chemoat- 
tractant FMLP. 
Decreased IL-I Binding Is Determined by Loss of Surface IL- 
1R.  Having  found  that  FMLP  drastically  reduced  IL-1 
binding to PMN, we examined whether this effect was due 
to a change in receptor affinity and/or a reduction in receptor 
number. Fig. 1 shows a saturation curve of IL-1 binding on 
untreated and FMLP-treated PMN. Scatchard analysis (Fig. 
1) demonstrated that FMLP reduced the number of IL-1R 
on PMN surface. In this particular experiment, the number 
of IL-1R per cell was 517 in untreated and 79 in FMLP-treated 
PMN. No significant change in receptor affinity was detected 
(kD values:  5.5  x  10-10 M  and 4  x  10-10 M in untreated 
and treated cells,  respectively). 
Kinetics and Dose-Response of lL-lfl Binding Loss Induced 
by FMLP.  PMN were cultured alone or with FMLP (10-; 
M) for various periods of time.  Next, cells were recovered 
and  examined  for  128I-IL-1 binding.  Culture  of PMN  in 
medium alone caused a modest and slow reduction of IL-1/3 
binding (Fig. 2). However, reduction of IL-1/3 binding in- 
duced by FMLP in PMN was rapid and pronounced. As shown 
in Fig.  2, IL-1/3 binding was reduced by 50%  at 30 s, the 
earliest measurable time point. Maximal reduction was reached 
after 30 rain. Thereafter, no further consistent reduction of 
IL-1 binding on treated PMN was  evident (not shown). 
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Figure  1.  Saturation curve and Scatchard analysis of ~25I-Ibl binding 
to PMN treated with FMLP. (.4) PMN were either untreated or treated 
with 10 -7 M FMLP for 30 rain. Cells were then incubated with 1.5-0.2 
nM 125I-IL-13,  in the presence or absence of a 100-M excess of unlabeled 
IL-13. Data are expressed as cpm specific bound to 3 x  106 cells. Similar 
results were obtained in two experiments. (B) Scatchard analysis of the 
saturation curve shown in A. ([-]), control; (1),  FMLP. 
A  dose-response curve of FMLP is  shown in  Fig.  3,  in 
which PMN from the same preparation were tested in par- 
allel  for IL-13 binding and chemotaxis.  The half-maximal 
response  was  reached  for  both  IL-13  binding  loss  and 
chemotaxis at ~5  x  10 -9 M. The two activities considered, 
IL-1 binding loss and chemotaxis, peaked at the same FMLP 
concentration  (10 -7 M).  At  higher  doses  (10-s-10 -6 M), 
reduction of IL-1 binding was similar to the optimal concen- 
tration,  whereas  the  chemotactic response  at  10-5  M  was 
~70% of the maximal response. On the basis of these results, 
PMN were routinely incubated with 10-7 M  FMLP for 30 
rain  at  37~ 
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Figure  3.  Chemotaxis and loss of IL-1 binding capacity of PMN ex- 
posed to different  concentrations  of  FMLP. PMN were exposed to different 
concentrations of FMLP for 30 min and examined for IL-1  binding. The 
same PMN preparation was assayed for chemotactic responsiveness to 
different concentrations of FMLP. Results, expressed as the percentage of 
the maximal response obtained in each assay, are the mean, with range, 
of two experiments. ([~), 11.-1 binding loss; (,),  chemotaxis. 
Release  of the IL-1  Decoy RII.  IL-1 binding sites  could 
disappear from cell surface by internalization or release.  As 
shown in Table 2, the internalization process of receptor-bound 
IL-1 was not  affected by FMLP,  in that  the percentage  of 
internalized  IL-1R was not different at all  the time points 
studied, in untreated versus FMLP-treated cells.  To examine 
the possibility that FMLP induced the release of IL-1R from 
treated PMN, cells were incubated with FMLP, and the cell- 
free supernatants were recovered and examined by cross-linking 
with  125I-IL-1B.  As shown in Fig.  4,  FMLP-treated PMN 
released an IL-l-binding molecule of ~45 kD (after subtrac- 
tion of the IL-1B molecular weight).  The specific nature of 
the cross-linking was demonstrated by competition with an 
excess  of unlabeled  IL-1. IL-1 binding product was totally 
inhibited by the presence of a blocking mAb (M22) directed 
against the IL-1 decoy RII but not by an anti-IL-1RI mAb 
(M1).  These observations were confirmed and extended  to 
other stimuli that induced reduction of IL-1 binding on human 
PMN.  As shown in Fig.  4,  C5a and  A23187 also induced 
the release by PMN of an IL-l-binding molecule identified 
Table  2.  Effect  of FMLP on Internalization 
of IL-IR  in Human PMN 
Percent  IL-1 internalized 
lo0 
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Figure  2.  Kinetics of II:1 binding loss induced by FMLP on PMN. 
PMN were incubated with 10- 7 FMLP for the indicated periods of time 
and then examined for 1I.-1 binding. Data are expressed as the percentage 
of specific IL-1  binding with respect to PMN at time 0. Data are expressed 
as the mean +  SD of three experiments. (~,),  control; ([]), FMLP. 
Time of incubation  Medium  FMLP 
min  10 -7 M 
0  4  _+  1.0  9  _+  5.0 
15  17  _+  0.1  21  x  1.6 
30  25  _+  0.8  27  •  2.0 
40  34  _  3.0  31  _+  1.5 
IL-1R internalization in the presence or absence of FMLP was assessed 
as detailed in Materials and Methods. The numbers in the table are the 
percentage of pellet-associated (internalized) specific  radioactivity  over the 
radioactivity present on cell surface at the end of the binding at 4~ 
(mean  _+  SD of three independent experiments). 
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from PMN. PMN were cultured  with or without the indicated stimuli 
for 30 min in serum-free  KPMI 1640. Supernatants were then recovered, 
concentrated,  combined  with lzsI-IblB, and examined  by chemical  cross- 
linking with disuccinimidyl  suberate  and SDS-PAGE.  Competitors  added 
before cross-linking were a 100-fold  excess of cold (unlabded) cytokine 
or 10 #g/ml anti-IL-1Rl (mAb M1) or anti-IblRII (mAb M22). 
as a soluble form of the IL-1 decoy RII.  Thus,  the loss  of 
IL-1 binding induced by chemoattractants is largely, if not 
exclusively, accounted for by release in a soluble form of IL-1 
decoy KII from the PMN  surface. 
Specificity of  lL-1 Binding Loss Induced by FMLP,  To study 
the specificity of FMLP-induced reduction of IL-1 binding, 
PMN treated with FMLP 10-7 M were examined for the ex- 
pression of other surface molecules. As shown in Table 3, 
FMLP, while reducing IL-1 binding, did not affect the ex- 
pression of CD18 and MHC class I molecules. Expression 
of CD16 was not reduced by FMLP treatment. Furthermore, 
binding of t25I-IL-8 was not significantly affected by treat- 
ment with FMLP.  These results indicate that  the decrease 
of IL-1 binding induced by FMLP in human PMN is con- 
siderably selective. 
Role  of Protein Synthesis  and  Proteolytic Enzymes.  IL-1 
binding loss  on PMN treated with FMLP did not require 
de novo protein synthesis. As shown in Table 4, the presence 
of the protein synthesis inhibitor CH did not affect the reduc- 
Table 4.  Effect  of Protein Synthesis Inhibition on FMLP-induced 
Loss of IL-I  Binding in PMN 
IL-1 binding 
Specific  Percentage 
Treatment  CH  cpm bound  of control 
Medium 
FMLP (10  .7 M) 
10/~g/ml 
-  920  +  171  100.0 
+  712  _+  69  77.3 
-  189  _+  58  20.5 
+  131  +  97  14.2 
PMN were incubated with the indicated agents for 30 min at 37~  and 
then examined  for binding of ml-IL-1. Data are shown as specific  bind- 
ing of labeled IL-1 _+ SD of triplicates. Similar  results were obtained in 
two experiments. 
tion of IL-1 binding induced by FMLP. CH alone slightly 
reduced IL-1 binding  (23%  reduction) on PMN. 
To test whether proteolytic cleavage could be responsible 
for FMLP-induced release  of IL-1 decoy KII,  PMN  were 
treated with FMLP in the presence or absence of different 
protease inhibitors (Table 5).  All the inhibitors were tested 
at the highest nontoxic dose (trypan blue dye exclusion) as 
assessed in preliminary experiments (data not shown). PMSF 
at 1 mM only partially blocked the effect of FMLP (44-56% 
inhibition of FMLP activity). TICK inhibited FMLP effect 
by  36%  at  0.5  mM.  c~l-Antitrypsin  strongly  inhibited 
FMLP activity (77% inhibition). By contrast, TPCK, an- 
other serine-threonine protease inhibitor, as well as chelators 
of Mg +§  and Ca + + cations (EGTA and EDTA), failed  to 
affect FMLP-induced IL-1 binding loss  on PMN. 
IL-IR Reexpression.  Next, we examined whether FMLP- 
induced release of IL-1K was followed by reexpression of IL- 
1K on PMN surface. Results are shown as percentage of IL-1 
binding in the FMLP-treated population versus the untreated 
cells at each time point. As shown in Fig. 5, FMLP induced 
Table 3.  Specificity  of Release of lL-1R  in FMLP-treated  PMN 
Expression of 
Treatment  IL-1R*  IL-8R*  CD16'  MHC class I*  CD18' 
Medium  5,200  •  604  40,398  _+  4,768  291  548  433 
FMLP  1,300  +  150  s  32,875  +  8251r  324  537  430 
PMN were incubated with or without FMLP for 30 min, Cells were then washed and examined for binding of radiolabeled IL-1 and IL-8, or for 
expression of CD16, MHC class I, and CD18 antigens by flow cytometry. Results are a compound of three different experiments. 
* Specific cpm bound -+ SD from triplicates. 
Mean channel of fluorescence. 
S  P <0.01. 
I[ Not significant. 
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IL-1 binding 
Experiment  FMLP +  Percent inhibition 
Protease inhibitor  number  FMLP  inhibitor  of FMLP activity* 
Percentage of control 
c~l-antitrypsin  (100/xg/ml)  1  43  90 
2  34  98 
3  30  69  77  +_  20 
PMSF  (1  mM)  1  30  62 
2  26  62 
3  43  75 
4  20  55  49  +  5 
TLCK (0.5  raM)  1  30  50 
2  40  63 
3  34  62  36  _+  7 
TPCK (100/~M)  1  27  24  -4 
EDTA (5  raM)  1  20  23 
2  30  28 
3  27  31  2  _+  4 
EGTA (1  mM)  1  20  17 
2  30  28 
3  33  35  -1  _+  4 
Cells were incubated with FMLP (10 -7 M) alone or with the indicated inhibitor  for 30 min and subsequently tested for IL-1 binding. 
" Percentage of inhibition was calculated as {[(FMLP + inhibitor) - (FMLP)]/[100- (FMLP)]} ￿  100. 
a 65% reduction of IL-1 binding tested after 30 min (time 0  -~ 
of recovery) of incubation.  After a recovery period  of 4  h, 
PMN  showed an IL-1 binding  level comparable to that  of 
the untreated population. To define whether IL-1R reexpres-  , 
sion required  protein  synthesis,  CH was added  during  the 
recovery period. As shown in Fig. 5, recovery of IL-1 binding 
after pretreatment with FMLP was inhibited by the presence 
of CH  during  the  recovery period.  ~  _ 
Responsiveness to IL-1 after IL-1 Decoy RII Stripping.  It was  ~- 
important  to assay whether chemoattractant-induced  strip- 
ping of a substantial fraction of membrane IL-1 decoy receptor 
was associated with a loss of IL-1 responsiveness. PMN were  -~ 
exposed to FMLP  (10-7  M)  for 30  min,  carefully washed,  ~ 
and pulsed for 3  h  with  IL-1 (2-20  ng/ml).  After removal 
of IL-1 by washing,  cells were incubated  for 24-72  h,  and 
the responsiveness of PMN  to IL-1 was observed in terms 
of cytokine production (IL-6 and IL-8) and prolongation of 
survival. IL-1 was a poor inducer of cytokine production in 
PMN compared to LPS used as positive control, with weak 
but  significant responses in only three out  of seven donors 
tested. FMLP did not reduce IL-l-induced cytokine produc- 
tion (not shown). FMLP treatment slightly, but not signifi- 
cantly,  augmented the IL-l-induced prolongation  of PMN 
100  ~ 




0  ￿9  ,  ,  ,  ,  .  ,  .  n 
1  2  :~  4  5 
Recovery  time  (hours) 
Figure 5.  Reexpression of II~IR on FMLP-treated PMN. PMN were 
treated with or without  FMLP (10-7 M, 30 min), After washing (time 
of recovery = 0), cells were incubated for various periods of time in RPMI 
1640 with 10% FCS medium in the presence or absence of 10 #g/ml CH. 
Next, cells were examined for II.-1  binding. Data are expressed as the per- 
centage of IL-1 binding with respect to medium-treated cells at each time 
point (mean, with range, of two experiments). ([]), medium; (0), cyclo- 
heximide. 
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pared to 49  +  3% of cells exposed to IL-1 alone (mean _+ 
SD of three experiments). 
Discussion 
The results presented here show that molecules represen- 
tative of different classes of chemotactic agents, including 
formyl peptides, complement components, lipid metabolites, 
and chemokines, cause rapid loss of IL-1R from human PMN. 
Receptors for the chemoattractants considered in the present 
study are seven transmembrane-spanning proteins coupled to 
G proteins.  By and large, increases in intracellular flee Ca + + 
and PKC activation are early events associated with chemoat- 
tractant activation of PMN (19). The PKC activator PMA 
and the Ca + §  ionophore A23187  mimicked the action of 
chemoattractants in causing rapid and extensive loss of IL-1 
binding in PMN. 
Loss of IL-1 binding capacity in chemoattractant-treated 
PMN was due to the disappearance of the receptors on the 
cell surface, and it was associated with the release of a 45-kD 
IL-l-binding molecule. The rate of IL-1R internalization was 
not affected by FMLP.  The 45-kD IL-l-binding molecule 
was identified as the IL-1 decoy KII, which represents the 
main IL-1R in myelomonocytic  cells and an anti-IL-1 pathway 
(2,  4,  11). 
Induction of IL-1 decoy RII release by chemoattractants 
was considerably selective, in that integral type I membrane 
(MHC class I, CD18, IL-SR) and phosphatidyl inositol-linked 
proteins  (CD16)  were unaffected under  these  conditions. 
Under very similar experimental conditions, various PMN 
activators, including chemoattractants, have been reported to 
cause rapid release of TNFR, and, under certain conditions, 
TNFR shedding is preferential for the p75 form (12,  20). 
In the present study, we could not identify induction of re- 
lease of the signal-transducing IL-1RI, in that, by size and 
mAb blocking, only the IL-1 decoy RII was present in the 
supernatants of chemoattractant-treated PMN. Since the IL- 
1RI is present in minute amounts on the surface of PMN 
(1, 2, 4), some release cannot be completely excluded at present. 
However, it should be noted that FMLP-treated PMN retain 
responsiveness to IL-1 in terms of weak cytokine production 
and prolongation of survival. It was previously demonstrated 
that the response of myelomonocytic cells to IL-1 is medi- 
ated by the signal-transducing IL-1RI (3, 4). Thus, the main- 
tenance of IL-1 responsiveness in FMLP-treated myelomono- 
cytic cells suggests, at minimum, that su~cient numbers of 
the IL-1RI are retained in the face of loss of 70-80%  IL-1 
decoy RII.  By and large, these data, showing IL-1 respon- 
siveness after shedding of 70-80%  IL-1 decoy RII, are con- 
sistent with the viewpoint that this molecule is not involved 
in signal transduction in myelomonocytic cells. 
We previously found that certain cytokines (IL-4, IL-13) 
and glucocorticoid hormones augmented IL-1 decoy RII in 
PMN,  in a transcription- and protein synthesis-dependent 
way (4, 10, 11). Up-regulation of newly synthesized receptor 
on PMN surface was paralleled by the release of soluble IL-1 
decoy RII from PMN cultivated for a relatively long period 
of time (>12 h) (4, 10, 11). Others found a soluble IL-1 decoy 
RII in biological fluids or supernatants from mitogen-activated 
mononuclear cells (5-9). Here we describe a different mech- 
anism of release of the IL-1 decoy RII, in which shedding 
of preformed IL-1 decoy RII from the PMN surface is ob- 
tained in seconds and does not require protein synthesis. It 
is interesting to note that the above-mentioned stimuli were 
poorly effective in inducing the rapid release of IL-1 decoy 
RII  (our unpublished data),  suggesting that  at least  two 
different levels of control, activated by different classes of ex- 
ternal signals,  exist. 
The biochemical process involved in rapid release of IL-1 
decoy KII from activated PMN is still  poorly understood. 
In the limited series of protease inhibitors tested here, certain 
molecules could, at least partially, prevent FMLP-induced re- 
lease of IL-1 decoy RII. Interestingly, the protease inhibitor 
oll-antitrypsin was the most effective one. Since we found 
that intact protein synthesis is not required for FMLP-induced 
release of IL-1 decoy RII, these data favor the possibility that 
a preformed proteolytic enzyme is involved. Rapid release 
of TNFR was not inhibited by PMSF or by other protease 
inhibitors (12), possibly suggesting that mechanisms involved 
in rapid release of IL-1R and TNFR from FMLP-activated 
PMN could be different. 
In addition to migration, chemoattractants cause a com- 
plex spectrum of responses in PMN, including the oxidative 
burst and enzyme release. Typically, myelomonocytic  cells ex- 
hibit different dose-response curves in terms of migration 
versus other functions. Chemotaxis dose-response curves are 
usually bell shaped, with EDs0 considerably lower (usually 
1 log) than those required, for instance, for oxidative burst. 
In the present study, we found that, with FMLP, the EDs0 
and peak concentrations for chemotaxis and for IL-1 decoy 
RII release were identical, though IL-1 decoy RII shedding 
did not decrease substantially at supraoptimal agonist con- 
centrations. In the same vein, FMLP-induced release of IL-1 
decoy RII was extremely rapid, reaching 50% of maximum 
at 30 s, the earliest measurable time point. The effective con- 
centration range, similar to that required for chemotaxis, and 
the time frame (seconds) of chemoattractant-induced IL-1 
decoy KII release are consistent with the view that, in the 
multistep process of PMN recruitment, IL-1 decoy RII shed- 
ding is an early event, already occurring in the blood com- 
partment. 
The  in  vivo  pathophysiological  significance of chemo- 
attractant-induced IL-1 decoy RII and TNFK (12) release 
is a matter of speculation. Administration of chemoattrac- 
tants in the circulation causes inhibition of local inflamma- 
tory  reactions  elicited by  various  agents,  including  IL-1 
(21-23). Rapid release of IL-1 decoy RII and TNFR might 
contribute to the seemingly paradoxical antiinflammatory ac- 
tivity of systemically administered chemoattractants. Chemo- 
attractant-induced release in the circulation of IL-1 decoy RII, 
an early event in recruitment, may provide a safeguard mech- 
anism against IL-1  leaking from inflamed tissues. 
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